Physician profile
William E Austin
NPI 1386758282
$1,342.26
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $210 · 2021: $19.87 · 2022: $147 · 2023: $114 · 2024: $17.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $131.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $358.84 | 2019-2023 | Viberzi, Linzess |
| Pfizer INC. | $155.09 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.67 | 2019-2020 | |
| Qol Medical, LLC | $111.99 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.58 | 2019-2020 | |
| Daiichi Sankyo INC. | $83.42 | 2019-2022 | |
| Janssen Biotech, INC. | $81.63 | 2019 | |
| Shionogi INC | $44.91 | 2019 | |
| Gilead Sciences, INC. | $41.74 | 2019-2023 | |
| Ucb, INC. | $41.61 | 2019-2020 | |
| Shire North American Group INC | $39.30 | 2019 | |
| Intercept Pharmaceuticals, INC. | $29.31 | 2019-2020 | |
| Celgene Corporation | $28.08 | 2022 | |
| Merck Sharp & Dohme LLC | $26.98 | 2020-2023 | Dificid |
| Organon LLC | $16.98 | 2023 | Hadlima |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $16.45 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.29 | 2022 | |
| Dova Pharmaceuticals | $15.75 | 2019 | |
| Amgen INC. | $15.65 | 2020 | |
| Ferring Pharmaceuticals INC. | $14.99 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.